Study on Amivantamab and Lazertinib with Chemotherapy for EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure

Inclusion Criteria

• Have at least one tumor that can be measured and has not been treated with radiation.
• Have advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations (Exon 19del or Exon 21 L858R).
• If there is a history of brain metastases, all brain lesions must have been treated and stable, with no need for further treatment.
• Have a good overall health status, with an ECOG score of 0 or 1.
• Any side effects from previous cancer treatments must have improved to a mild level or returned to baseline.
• Women of childbearing potential must have a negative pregnancy test before starting treatment and agree to regular pregnancy tests during the study.
• Must have experienced cancer progression after treatment with osimertinib, which was given as the most recent therapy for advanced disease.
• Must stop taking osimertinib at least 8 days before starting the study treatment.

Exclusion Criteria

• Have received radiation therapy for symptom relief less than 14 days before starting the study.
• Have worsening or symptomatic brain metastases.
• Have a history of leptomeningeal disease or untreated spinal cord compression.
• Have a known transformation to small cell lung cancer.
• Have a history of lung diseases like interstitial lung disease or radiation pneumonitis.
• Have significant heart or blood vessel problems, such as recent blood clots, heart attack, or stroke, and are not on proper blood-thinning medication.